Last reviewed · How we verify
ZSP1603
At a glance
| Generic name | ZSP1603 |
|---|---|
| Sponsor | Guangdong Raynovent Biotech Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Tolerability, Pharmacokinetics and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis （IPF） (PHASE1, PHASE2)
- Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose of ZSP1603 in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ZSP1603 CI brief — competitive landscape report
- ZSP1603 updates RSS · CI watch RSS
- Guangdong Raynovent Biotech Co., Ltd portfolio CI